{
    "Trade/Device Name(s)": [
        "MDT2 BLE Self-Monitoring Blood Glucose System"
    ],
    "Submitter Information": "EPS Bio Technology Corp.",
    "510(k) Number": "K190189",
    "Predicate Device Reference 510(k) Number(s)": [
        "K133389"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "November 1, 2019",
    "Summary Letter Received Date": "October 2, 2019",
    "Submission Date": "October 1, 2019",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MDT2 BLE meter"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical biosensor technique",
        "FAD glucose dehydrogenase enzymatic reaction"
    ],
    "Methodologies": [
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "Test Strip"
    ],
    "Document Summary": "FDA 510(k) summary for MDT2 BLE Self-Monitoring Blood Glucose System with Bluetooth-enabled meter for home blood glucose testing",
    "Indications for Use Summary": "Intended for quantitative measurement of glucose in fresh capillary whole blood from fingertip, palm, or forearm, for home use by a single patient with diabetes, not for neonates or diagnosis/screening of diabetes, including alternative site testing during steady-state glucose conditions",
    "fda_folder": "Clinical Chemistry"
}